$GILD Headlines Speculators should retain a flexible

New Post Public Reply Private Reply Replies (0) Message Board

Dec 6, 2013 at 11:31 AM

$GILD Headlines

Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt

Wall Street Breakfast: Must-Know News 6:33 a.m. Today - Seeking Alpha
Leukemia drugs in focus at hematology meeting 4:34 a.m. Today - Seeking Alpha
4 Potential Blockbuster Drugs Awaiting Launch 5:21 p.m. Dec. 5, 2013 - Investors Business Daily
Are Biotech ETFs Back on Track? - ETF News And Commentary 12:04 p.m. Dec. 4, 2013 - Zacks.com
Update on Gilead's Legal Troubles - Analyst Blog 11:40 a.m. Dec. 4, 2013 - Zacks.com
Biotech Stock Predictions 2014: Vertex is Bought, Alexion Sinks, BlueBird Flies And More 11:35 a.m. Dec. 4, 2013 - TheStreet.com
Biotech Stock Roundup: CBST Hits 52-Week High, OREX Lights Up - Analyst Blog 10:59 a.m. Dec. 4, 2013 - Zacks.com
Time to Reconsider Sector Weights 10:00 a.m. Dec. 4, 2013 - RealMoney.com
Best Biotech CEO of 2013: Your Vote Counts 8:07 a.m. Dec. 4, 2013 - TheStreet.com
Medidata, CaesarStone Among New Buys Of Top Funds 5:41 p.m. Dec. 3, 2013 - Investors Business Daily
Chipotle, Cognizant: Stocks That Frank Caruso Likes 5:41 p.m. Dec. 3, 2013 - Investors Business Daily
Gilead Sciences Inc (GILD): Today's Featured Health Care Laggard 5:03 p.m. Dec. 3, 2013 - TheStreet.com
Limited impact on Gilead expected from Idenix lawsuit: Wells 11:40 a.m. Dec. 2, 2013 - Seeking Alpha
Idenix initiates Phase 2 HCV trial, files patent infringement suits against Gilead 8:38 a.m. Dec. 2, 2013 - Seeking Alpha
Weekly Top Insider Sells: GOOG, FCX, GILD, P, OCN 8:22 a.m. Dec. 2, 2013 - GuruFocus.com
Idenix Pharmaceuticals Files Patent Infringement, Interference Lawsuits Against Gilead Sciences 6:08 a.m. Dec. 2, 2013 - benzinga.com
3 Invesco Funds Delivering Great Returns (revised) - Analyst Blog 11:50 a.m. Nov. 29, 2013 - Zacks.com
UPDATE: Piper Jaffray Initiates Coverage on Gilead Sciences on Expected Attractive Returns 10:16 a.m. Nov. 27, 2013 - benzinga.com
Biotech Stock Roundup: EU News Boosts Biogen, Gilead & Celgene - Analyst Blog 10:01 a.m. Nov. 27, 2013 - Zacks.com
Healthcare coverage initiations roundup 8:55 a.m. Nov. 27, 2013 - Seeking Alpha

Gilead Sciences to Present at the NASDAQ OMX 30th Investor Program on Tuesday, December 3 5:00 p.m. Dec. 2, 2013 - BusinessWire
Critical Alerts For General Electric, Gilead Sciences, Morgan Stanley, Qualcomm, and Adobe Released By InvestorsObserver 9:31 a.m. Dec. 2, 2013 - PR Newswire
Market Expert Opinion: Gilead Sciences, NPS Pharma, InterMune, and Halozyme Therapeutics 8:40 a.m. Dec. 2, 2013 - PR Newswire
Gilead Sciences, Inc. Uses the PHT Corporation LogPad(R) System for 1st Antianginal Drug to Treat Type 2 Diabetes 8:00 a.m. Dec. 2, 2013 - BusinessWire
Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits Against Gilead Sciences 7:00 a.m. Dec. 2, 2013 - GlobeNewswire
Early Morning Buzz: Groupon, Gilead Sciences, Eltek Ltd, Alcatel Lucent SA 9:47 a.m. Nov. 27, 2013 - ACCESSWIRE
Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare 8:00 a.m. Nov. 27, 2013 - PR Newswire
Clinical Studies, Convertible Senior Notes, and Commercial Supply Contracts - Research Report on Gilead, Hologic, Regeneron, OPKO, and Unilife 8:00 a.m. Nov. 25, 2013 - PR Newswire
European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi(R) for the Treatment of Chronic Hepatitis C Infection 8:47 a.m. Nov. 22, 2013 - BusinessWire
Stock Price Movement, Grants for Projects, and Clinical Data Presentations - Research Report on Gilead, Bristol-Myers Squibb, HCA, Allergan, and Alexion 8:00 a.m. Nov. 20, 2013 - PR Newswire
Gilead's Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study 9:17 a.m. Nov. 18, 2013 - BusinessWire
European Commission Approves Gilead's Vitekta(TM), an Integrase Inhibitor for the Treatment of HIV-1 Infection 8:00 a.m. Nov. 18, 2013 - BusinessWire
Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13 4:31 p.m. Nov. 12, 2013 - BusinessWire
Insider Trading Reports for Facebook, Microsoft, Gilead Sciences, Bank of America, Riverbed, and Wells Fargo 8:55 a.m. Nov. 11, 2013 - PR Newswire
S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting 9:00 a.m. Nov. 7, 2013 - BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind 8:00 a.m. Nov. 6, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc. 11:14 a.m. Nov. 4, 2013 - PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda 8:00 a.m. Nov. 4, 2013 - PR Newswire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation 9:01 a.m. Nov. 2, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Podcast Giants Converge in Tennessee for POD U Summit

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Pathalys' Phase 3 Data Shows Promise for CKD Drug

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

Millrose Faces Securities Fraud Suit Amidst Decline

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...

Monterey Desalination Project: Costs, Challenges & Future

Water Woes Dragging on in Monterey? Alright, let's dive into the nitty-gritty of this water supply saga in the Monterey Peninsula. If you're wondering why California American Water is hustling so hard, it's because the taps around here ain't running like they should. This mess has been stretching on for ages, with everyone thirsty for a sustainable answer. The Cost of...

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Think Together Marks 20 Years of ASES Impact in CA

Hands-on Learning: California's Bright Future Starts Here Who's ever thought a schoolyard's the same after three? Let me tell you, in California, it's staying alive and kicking, thanks to Think Together's whirlwind of celebrations for the After School Education and Safety (ASES) program. We're talking 450 schoolyard shindigs highlighting not just how far expanded learning...

Investor Yazan Al Homsi Backs Arcanus Aerial for $500K

Yazan Al Homsi Backs Canadian Innovation Every once in a while, you see a move in the market that feels bigger than the numbers on the page. That's what this $500,000 from Yazan Al Homsi into Arcanus Aerial Systems does. Al Homsi, a UAE-based investor with a solid pedigree, decided to pump half a million bucks into Arcanus just as it's setting down roots in Canadian soil...

Veterans Find Community and Wellness at Orland Hills Bash

A Celebration of Veterans and Community Orland Hills is set to light up with a unique Veterans Day Bash on November 1, 2026. This isn't just your run-of-the-mill community gathering; it's an event that brings together veterans from all around for a day packed with resources, education, and a chance to connect with kindred spirits—all thanks to the collaboration between...

HumanView Relaunch: LEAP Group Decodes Customer Signals

Understanding Customer Signals Like Never Before Well, here's one for the ol' playbook. The LEAP Group just dusted off their tool, HumanView, like an old car getting a fresh coat of paint and an engine overhaul. It's been rebuilt from the ground up, promising to turn those random blips of online chatter into actionable business insights. Not the same old dashboard mumbo...

CapCut's AI Tools Reshape Video Content Creation

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...